Garcia F, Romeu J, Grau I, Sambeat MA, Dalmau D, Knobel H, Gatell JM, Miro JM; International Conference on AIDS.
Int Conf AIDS. 1998; 12: 59 (abstract no. 12238).
Spanish EARTH Study Co-ordinating Committee, Spain.
BACKGROUND: The objective was to test whether maintaining a pre-established viral load (VL) reduction can delay progression in asymptomatic HIV-1 infected patients with CD4+T cell count > or = 500 x 10(6)/L and viral load > or = 5000 copies/ml. End points were evolution to < 500 CD4+ plus 2 symptoms of the category B, < 350 CD4+, category C or death. METHODS: Patients were randomly assigned to no treatment (N = 16), ZDV plus 3TC (N = 29), d4T plus 3TC (N = 30), d4t plus 3TC plus indinavir (N = 39). Recruitment of the control group was discontinued when the preliminary analysis of a similar study (Spanish EARTH-1) showed a worse outcome compared to all treatment arms. VL was measured at baseline at 1/2, 1, 2 and 4 months and every 4 months thereafter. Active treatment could be modified whenever necessary to maintain the targeted viral load reduction (< 1500 copies/ml in double therapy groups and < 200 copies/ml in triple therapy group). VL was also measured after 1/2 month and one month after every change in the therapeutic strategy. RESULTS: After 16 weeks of follow-up the virological response was: TABULAR DATA, SEE ABSTRACT VOLUME. within brackets are number of patients at risk No patients progressed to study end-points. Pre-established viral load reduction was maintained in all the patients: CONCLUSIONS: At 16 weeks of follow-up the proportion of patients with an undetectable level of viral load (< 200 copies/ml) was significantly higher in patients on triple therapy than in patients with double therapy in individuals with CD4+ T cell count > or = 500 x 10(6)/L and viral load > or = 5000 copies/ml. Longer follow-up, and VL measurements with an ultrasensible assay will be presented.
Publication Types:
Keywords:
- AIDS Vaccines
- Acquired Immunodeficiency Syndrome
- Anti-HIV Agents
- Antiretroviral Therapy, Highly Active
- Biomedical Research
- CD4 Lymphocyte Count
- Disease Progression
- Drug Therapy, Combination
- HIV
- HIV Infections
- HIV Protease Inhibitors
- HIV Seropositivity
- HIV-1
- Humans
- Indinavir
- Lamivudine
- Stavudine
- Viral Load
- Zidovudine
- drug therapy
- therapy
Other ID:
UI: 102227266
From Meeting Abstracts